Shares of Akebia Therapeutics Inc (NASDAQ:AKBA) have earned a consensus recommendation of “Hold” from the twelve ratings firms that are currently covering the stock, MarketBeat.com reports. Three equities research analysts have rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $22.50.
Several equities analysts have commented on AKBA shares. ValuEngine cut shares of Akebia Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. BTIG Research started coverage on shares of Akebia Therapeutics in a research report on Thursday, December 7th. They issued a “buy” rating and a $30.00 price target for the company. Piper Jaffray Companies started coverage on shares of Akebia Therapeutics in a research report on Monday, December 18th. They issued an “overweight” rating and a $26.00 price target for the company. Zacks Investment Research lowered shares of Akebia Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, January 2nd. Finally, Mizuho restated a “buy” rating and issued a $24.00 price objective on shares of Akebia Therapeutics in a report on Tuesday, February 13th.
Institutional investors and hedge funds have recently made changes to their positions in the company. Macquarie Group Ltd. acquired a new stake in shares of Akebia Therapeutics in the 3rd quarter valued at $183,000. Teacher Retirement System of Texas acquired a new stake in shares of Akebia Therapeutics in the 4th quarter valued at $188,000. Campbell & CO Investment Adviser LLC acquired a new stake in Akebia Therapeutics during the 3rd quarter worth $200,000. Caxton Associates LP acquired a new stake in Akebia Therapeutics during the 3rd quarter worth $246,000. Finally, Voya Investment Management LLC raised its stake in Akebia Therapeutics by 11.7% during the 2nd quarter. Voya Investment Management LLC now owns 18,454 shares of the biopharmaceutical company’s stock worth $265,000 after acquiring an additional 1,933 shares in the last quarter. Institutional investors and hedge funds own 71.23% of the company’s stock.
Akebia Therapeutics (AKBA) opened at $12.30 on Friday. Akebia Therapeutics has a 1 year low of $8.69 and a 1 year high of $20.25. The firm has a market cap of $576.29, a PE ratio of -6.41 and a beta of 0.80.
Akebia Therapeutics (NASDAQ:AKBA) last issued its quarterly earnings results on Monday, March 12th. The biopharmaceutical company reported $0.25 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.36) by $0.61. Akebia Therapeutics had a negative net margin of 43.21% and a negative return on equity of 100.28%. The company had revenue of $87.32 million during the quarter, compared to analysts’ expectations of $66.00 million. research analysts forecast that Akebia Therapeutics will post -2.04 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: This story was first published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this story on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this story can be accessed at https://ledgergazette.com/2018/03/17/akebia-therapeutics-inc-akba-given-consensus-rating-of-hold-by-brokerages.html.
About Akebia Therapeutics
Akebia Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company’s lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD).
Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.